… ) performance status less than 4, were stratified by bone marrow and performance status
and randomized to … , progression-free and overall survival, toxicity, and performance status. …

… randomized controlled trial that incorporated performance … It was important that the performance
status scale used was … to determine the performance status measure most appropriate …

… Methods: In a Brazilian multicenter phase III randomized trial, advanced NSCLC patients, …
prior chemotherapy, and adequate organ function, were randomized to P alone (500 mg/m2) …

… status, self-reported HRQoL and performance status at the pre-planned interim analysis of
the trial. As such, the data presented herein may offer important implications for the provision …

… A total of 859 patients were randomized to the four treatment arms, and 779 cases were …
Seventy-eight percent of patients had a Karnofsky performance status between 70-100, 18% 50-…

… highlight the importance of assessing survival when investigating therapeutic management
of cachexia and support the use of WL as a stratifier (independent of performance status). …

Background: The optimal treatment of patients with advanced NSCLC and PS2 has not been
resolved. A retrospective analysis of 99 patients with PS2 in CALGB 9730 (Lilenbaum, JCO …

… NSCLC with good performance status typically receive … Methods: This open-label, randomized,
multicenter, phase II … or metastatic NSCLC with ECOG performance status ≤1. Pts treated …

… patients were randomized to receive … performance status of 0 or 1 versus 2. Toxicity was
greatest with D100, but the D75 arm was well-tolerated. CONCLUSION: This first randomized …

… Patients were required to have an Eastern Cooperative Oncology Group performance status
of 0 to 2, adequate bone marrow, (absolute granulocyte count ≥ 2,000/mmc, platelets ≥ …